Fig. 3.
EpFAs attenuated PA-caused injury to the renal mesangial cells (mRMCs) by activating Pax2 and Ampk. The treatment of PA modified mRNA levels of (A) Mcp-1, (B) Ampk, and (C) Pax2 in mRMCs both dose- and time-dependently. For A–C, unfilled circles, green diamonds, and red dots indicated the mRMCs were treated with PA at 0, 100, and 300 μM, respectively. The high concentration of 14(15)-EET and the concentration of other EpFAs tested were 100 nM, while the lower concentration of 14(15)-EET was 10 nM. Treatment of EpFAs modified PA-mediated mRNA levels of (D) Mcp-1, (E) Ampk, and (F) Pax2 in mRMCs. Treatment of 14(15)-EET but not 14,15-DHET significantly reversed the PA-induced decrease of the protein levels of (G and H) p-Ampkα and (I and J) Pax2 in mRMCs (n = 4). Treatments of 14(15)-EET and 14,15-DHET to PA-mediated mRMCs resulted in similar changes in protein levels of p-Pax2 to those of Pax2, which were presented in SI Appendix, Fig. S7 C and D. Data represent mean ± SEM for A–F and mean ± SD for H and J; ns (no significant difference) P ≥ 0.05, 0.01 < *P < 0.05, 0.001 < **P ≤ 0.01, 0.0001 < ***P ≤ 0.001, and ****P ≤ 0.0001 were determined by two-tailed t test for A–F and ANOVA followed by Tukey’s or Games−Howell post hoc comparison test for H and J.